- Home
- NXDT vs TLSI Comparison
NXDT vs TLSI Comparison
Compare NXDT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXDT
- TLSI
- Stock Information
- Founded
- NXDT 2012
- TLSI 2010
- Country
- NXDT United States
- TLSI United States
- Employees
- NXDT N/A
- TLSI N/A
- Industry
- NXDT Investment Managers
- TLSI Medical Specialities
- Sector
- NXDT Finance
- TLSI Health Care
- Exchange
- NXDT Nasdaq
- TLSI Nasdaq
- Market Cap
- NXDT 187.7M
- TLSI 204.0M
- IPO Year
- NXDT N/A
- TLSI N/A
- Fundamental
- Price
- NXDT $4.70
- TLSI $5.07
- Analyst Decision
- NXDT
- TLSI Strong Buy
- Analyst Count
- NXDT 0
- TLSI 5
- Target Price
- NXDT N/A
- TLSI $10.90
- AVG Volume (30 Days)
- NXDT 133.6K
- TLSI 154.9K
- Earning Date
- NXDT 01-01-0001
- TLSI 08-13-2025
- Dividend Yield
- NXDT 9.66%
- TLSI N/A
- EPS Growth
- NXDT N/A
- TLSI N/A
- EPS
- NXDT 0.99
- TLSI N/A
- Revenue
- NXDT N/A
- TLSI $32,141,000.00
- Revenue This Year
- NXDT N/A
- TLSI $55.52
- Revenue Next Year
- NXDT N/A
- TLSI $54.76
- P/E Ratio
- NXDT $6.41
- TLSI N/A
- Revenue Growth
- NXDT N/A
- TLSI 46.20
- 52 Week Low
- NXDT $5.89
- TLSI $3.50
- 52 Week High
- NXDT $13.07
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- NXDT 70.00
- TLSI 45.72
- Support Level
- NXDT $3.80
- TLSI $4.81
- Resistance Level
- NXDT $4.53
- TLSI $5.63
- Average True Range (ATR)
- NXDT 0.20
- TLSI 0.35
- MACD
- NXDT 0.06
- TLSI -0.03
- Stochastic Oscillator
- NXDT 87.10
- TLSI 30.95
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.